The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Changhua site meets international regulatory standards for global medical applications
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
Subscribe To Our Newsletter & Stay Updated
